Short Note on Drug Development

L. Roche
{"title":"Short Note on Drug Development","authors":"L. Roche","doi":"10.35248/0975-0851.21.S2.E002","DOIUrl":null,"url":null,"abstract":"Bioavailability is alluded to as the degree and rate to which the dynamic medication fixing or dynamic moiety from the medication item is ingested and opens up at the site of medication activity. The general bioavailability as far as the rate and degree of medication ingestion is viewed as prescient of clinical results. In 1984, the United States Food and Drug Administration (FDA) was approved to endorse conventional medication items under the Drug Price Competition and Patent Term Restoration Act dependent on proof of normal bioequivalence in drug assimilation through the direct of bioavailability and bioequivalence considers.","PeriodicalId":15184,"journal":{"name":"Journal of Bioequivalence & Bioavailability","volume":"32 1","pages":"1-1"},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Bioequivalence & Bioavailability","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/0975-0851.21.S2.E002","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Bioavailability is alluded to as the degree and rate to which the dynamic medication fixing or dynamic moiety from the medication item is ingested and opens up at the site of medication activity. The general bioavailability as far as the rate and degree of medication ingestion is viewed as prescient of clinical results. In 1984, the United States Food and Drug Administration (FDA) was approved to endorse conventional medication items under the Drug Price Competition and Patent Term Restoration Act dependent on proof of normal bioequivalence in drug assimilation through the direct of bioavailability and bioequivalence considers.
关于药物开发的简述
生物利用度指的是动态药物固定物或药物项目的动态部分被摄入并在药物活性部位打开的程度和速率。一般的生物利用度,就药物摄取的速度和程度而言,被视为临床结果的先见之明。1984年,美国食品和药物管理局(FDA)根据《药品价格竞争和专利期限恢复法案》,通过直接考虑生物利用度和生物等效性,批准常规药物项目依赖于药物同化中的正常生物等效性证明。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信